THE MAIN CRITERIA FOR DETERMINING THE TACTICS OF MANAGEMENT OF PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19

The aim of the work is to present the main criteria for determining the management tactics of patients with a new coronavirus infection COVID-19.Material and methods. The results of clinical and laboratory examination and data on complex therapy of 52 patients with mod-erate and severe forms of new coronavirus infection are presented.Results. We have studied the main clinical and laboratory manifestations of COVID-19 (dry cough, shortness of breath, decrease in SpO2, increase in the level of CRP, D-dimer, and volume of lung tissue damage (CT 1-4)) in the dynamics of the disease and justified their significance as criteria for assessing the severity, stage of a new coronavirus infection, and severity of hyperinflammation syndrome. The tolerability and effectiveness of the main components of complex therapy in the studied patients with a new coronavirus infection were evaluated and the leading prognostic role of pathogenetically based immunosuppressive and anticoagulant therapy was confirmed.Conclusions. The severity of clinical and laboratory symptoms of COVID-19 depends on the severity of the disease. Proactive anti-inflammatory and anticoagulant therapy is crucial in the complex treatment of patients with a new coronavirus infection.

COVID-19, stages of the disease, severity, components of therapy

1. Клинико-лабораторные параллели при новой коронавирусной инфекции СOVID-19 и геморрагической лихорадке с почечным синдромом / Д.А. Валишин [и др.] // Медицинский вестник Башкортостана. - 2020. - Т. 15, № 3. - C. 86-90

2. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции COVID-19» (Версия 9 от 26.10.20). URL: https://static1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_%D0%9CR_COVID19_v9.pdf (дата обращения 20.10.2020)

3. Марцевич, С.Ю. Лечение больных COVID-19 и сопутствующими сердечно-сосудистыми заболеваниями: не забывать о принципах доказательной медицины / С.Ю. Марцевич // Рациональная фармакотерапия в кардиологии. - 2020. - Т. 16, № 2. - С. 273276. DOI:10.20996/1819-6446- 2020-04-11

4. Патофизиологические механизмы поражения легких при геморрагической лихорадке с почечным синдромом / М.А. Исакова [и др.] // Медицинский вестник Башкортостана. - 2009. - № 2. - С. 21-27

5. Abdulamir, A.S. The possible immunological pathways for the variable immunopathogenesis of COVID-19 infections among healthy adults, elderly and children / A.S. Abdulamir, R.R. Hafidh // Electron. J. Gen. Med. - 2020. - Vol. 17, № 4. - Р. em202

6. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 / P. Colson [et al.] // Int. J. Antimicrob. Agents. - 2020. - Vol. 55, № 4. - P. 105932. doi: 10.1016/j.ijantimicag.2020.105932

7. Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an openlabel non-randomized clinical trial / F. Gautret [et al.] // Int. J. Antimicrob. Agents. - 2020. - Vol. 56, № 1. - P. 105949. doi: 10.1016/j.ijantimicag.2020.105949

8. Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the Coronavirus Study Group / A.E. Gorbalenya [et al.] // Nature Microbiol. doi: 10.1038/s41564-020-0695-z

9. On the Alert for Cytokine Storm: Immunopathology in COVID-19 / L.A. Henderson [et al.] // Arthritis Rheumatol. - 2020. - Vol. 72, № 7. - P. 1059-1063. doi: 10.1002/art.41285

10. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China / C. Huang [et al.] // Lancet. - 2020. - № 395 (10223). - P. 497-506. doi: 10.1016/S0140-6736(20)30183-5

11. A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohis- tiocytosis in Adults / B. Kumar [et al.] // J. Clin. Immunol. - 2017. - Vol. 37, № 7. - P. 638-643. doi: 10.1007/s10875-017-0439-x

12. COVID-19: consider cytokine storm syndromes and immunosuppression / P. Mehta [et al.] // Lancet. - 2020. - № 395 (10229). - P. 1033-1034. doi: 10.1016/S0140-6736(20)30628-0

13. Rothan, H.A. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak / H.A. Rothan, S.N. Byrareddy // J Au- toimmun. - 2020. - № 109. - P. 102433. doi: 10.1016/j.jaut.2020.102433

14. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China / W. Zhang [et al.] // Clin. Immunol. - 2020. - № 214. - P. 108393. doi: 10.1016/j.clim.2020.108393

15. A pneumonia outbreak associated with a new coronavirus of probable bat origin / P. Zhou [et al.] // Nature. - 2020. - № 5791 (7798). - P. 270-273. doi: 10.1038/s41586-020-2012-7